2025-12-04 - Analysis Report
Okay, let's break down the analysis of Schrodinger Inc. (SDGR) based on the provided data.

**Company Overview:**

Schrodinger Inc. is a company focused on developing software for drug discovery and materials science.

**1) Return Rate Comparison:**

*   **SDGR Cumulative Return:** -56.96%
*   **VOO (S&P 500) Cumulative Return:** 68.74%
*   **Divergence:** -127.1 (Relative Divergence: 0.0)

**Analysis:** SDGR has significantly underperformed the S&P 500.  The divergence is extremely negative, indicating SDGR's returns are far below the benchmark. The relative divergence indicates that this is the worst divergence seen over the observed period.

**Alpha, Beta, CAGR, MDD Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2020-2022  | -70.0% | 78.2% | -76.0% | 0.0   | 1.4    |
| 2021-2023  | -57.0% | 81.0% | -59.0% | -0.0  | 2.6    |
| 2022-2024  | 6.0%  | 81.0% | -14.0% | -0.0  | 1.4    |
| 2023-2025  | -5.0%  | 82.6% | -70.0% | -0.0  | 1.3    |

**Analysis:**

*   **CAGR:** The compounded annual growth rate demonstrates poor performance for the first three-year periods.
*   **MDD:** The Maximum Drawdown is consistently very high, indicating significant risk and volatility. SDGR is subject to great loss from peak to trough.
*   **Alpha:** The negative Alpha values consistently indicate underperformance relative to the benchmark (S&P 500) after accounting for market risk.
*   **Beta:** Beta is at or near zero in each time frame, which indicates that the stock moves with almost no correlation to the movement of the overall stock market.
*   **Cap(B):** Market capitalization in Billions.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 17.26
*   **Last-market:** {'price': 17.27, 'previousClose': 17.08, 'change': 1.11}
*   **5-day SMA:** 17.36
*   **20-day SMA:** 17.69
*   **60-day SMA:** 19.31

**Analysis:**  The stock price closed slightly higher than the previous close, change of 1.11. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This suggests a downtrend in the stock price.

**3) RSI, PPO, and Hybrid Signal:**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI:** 39.12
*   **PPO:** 0.29
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (58 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -3.1 (단기하락 - short-term decline)
*   **Expected Return (%):** -6482.9%

**Analysis:**

*   **MRI:** A surprising indicator. Recommends High Investment.
*   **RSI:** The RSI is below 40, suggesting the stock is nearing oversold conditions.
*   **PPO:** The PPO being close to zero indicates the price moving average is stable and there are no extremes.
*   **Hybrid Signal:** Based on the MRI, the signal recommends a full investment with small monthly investments.
*   **Divergence:** The negative change suggests short-term downward momentum.
*   **Expected Return:**  The exceptionally negative expected return indicates a significant risk and a very pessimistic outlook.

**4) Recent News & Significant Events:**

*   **Positive Headlines:** Several headlines suggest a potential turnaround:
    *   "Unlocking Hidden Value In Schrodinger's Box" (Seeking Alpha)
    *   "Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now" (Yahoo Finance)
    *   "KeyBanc reiterates Overweight rating on Schrodinger stock with $28 price target" (Investing.com)
*   **Mixed Headlines:**
    *   "Understanding Momentum Shifts in (SDGR)"
    *   "VIX Spike: How risky is SDGR stock now"
*   **Earnings Report:** "Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates" (MSN)

**Analysis:** The news sentiment is mixed but leans slightly positive.  The "Buy the Bottom" and "Unlocking Hidden Value" articles, combined with the KeyBanc price target, suggest potential upside. However, the VIX spike article warns of risk. The Q3 earnings report shows a loss but exceeding revenue estimates is a positive sign.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~1.67 on a 1-5 scale)
*   **Target Price:**  Avg: $27.22 / High: $33.00 / Low: $18.00

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus and an average target price significantly above the current price. This suggests analysts believe the stock is undervalued.

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue  |
|------------|--------|----------|
| 2025-11-05  | -0.45 | 0.05 B$  |
| 2025-08-06  | -0.59 | 0.05 B$  |
| 2025-05-07  | -0.82 | 0.06 B$  |
| 2024-11-12  | -0.52 | 0.04 B$  |
| 2025-11-05  | -0.52 | 0.04 B$  |

**Analysis:**  The company is consistently losing money (negative EPS). While revenues are generally stable around $0.04-0.06 billion per quarter, they are not sufficient to generate a profit. The most recent EPS shows an improvement, however, the company is still underperforming.

**6) Financial Information (Revenue & Profitability, Capital & Profitability):**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|----------------|
| 2025-09-30 | $0.05B  | 51.61%        |
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-09-30 | $0.32B  | -10.21%   |
| 2025-06-30 | $0.34B  | -12.59%   |
| 2025-03-31 | $0.37B  | -16.01%   |
| 2024-12-31 | $0.42B  | -9.54%    |
| 2024-09-30 | $0.45B  | -8.49%    |

**Analysis:**

*   **Revenue & Profitability:** While revenue is relatively consistent, profit margins fluctuate, with a high in Q4 2024. The profit margin shows the business model can be very profitable.
*   **Capital & Profitability:** Equity is decreasing, indicating the company is burning through its assets. The negative ROE confirms the company is not generating profits relative to its equity.

**7) Comprehensive Analysis (Summary):**

Schrodinger (SDGR) presents a mixed picture.

*   **Negative Factors:** The stock has significantly underperformed the S&P 500, with a massive negative divergence. Historical CAGR and MDD figures highlight high volatility and poor returns. The company is consistently losing money, and equity is decreasing. The expected return is disastrously negative, and the short-term trend is downward.
*   **Positive Factors:** Recent news sentiment is cautiously optimistic, with articles suggesting potential value and a "buy the bottom" opportunity. Analysts have a "Buy" consensus with a significantly higher target price. Revenue numbers are stable. The recent MRI is high, with a hybrid signal recommending "Buy."

**Conclusion:**

Investing in SDGR is a high-risk, high-reward proposition. The company's fundamentals are currently weak, with consistent losses and decreasing equity. However, analyst optimism, positive news headlines, and a potentially oversold condition suggest a possible turnaround. Investors should carefully weigh the risks and conduct thorough due diligence before considering an investment in SDGR. The MRI is a curious outlier and should be viewed with suspicion. The vastly negative expected return should raise serious concerns.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.